"FDA is not acting to advance public health, protect women and the unborn, or stay in compliance with the law. Rather, it is attempting to fall in lockstep with the Biden Administration’s political agenda at the expense of the public interest."
As a result, Texas Attorney General Paxton has joined a Mississippi-led effort and amicus brief in a case challenging reckless and illegal actions by the FDA that expand access to abortion-inducing drugs being sent through the mail.
In this instance, FDA is not acting to advance public health, protect women and the unborn, or stay in compliance with the law. Rather, it is attempting to fall in lockstep with the Biden Administration’s political agenda at the expense of the public interest.
The amicus states:
“In 2016, the FDA rolled back many safety requirements — allowing mifepristone to be prescribed later in pregnancy, by non-doctors, and with only one in-person visit. In 2021, the agency halted the remaining in-person dispensing requirements during the COVID-19 pandemic and later abandoned the requirements altogether.
"After decades of such efforts, the FDA now broadly condones a wide-ranging mail-order abortion-drug regime. Plaintiffs here have moved to preliminarily enjoin and set aside the FDA’s actions.”
“In 2016, the FDA rolled back many safety requirements — allowing mifepristone to be prescribed later in pregnancy, by non-doctors, and with only one in-person visit. In 2021, the agency halted the remaining in-person dispensing requirements during the COVID-19 pandemic and later abandoned the requirements altogether.
"After decades of such efforts, the FDA now broadly condones a wide-ranging mail-order abortion-drug regime. Plaintiffs here have moved to preliminarily enjoin and set aside the FDA’s actions.”
Paxton also recently sent a letter to the FDA criticizing the rule change.
- To read the full amicus brief, click here.
